cached image
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Leah Caroline Thomas Byrne is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2014 — 2016 |
Byrne, Leah |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Optimizing Gene Therapies in Large Animal Models of Retinal Degeneration @ University of Pennsylvania
7. Project Summary/Abstract Photoreceptors (PRs) and retinal pigment epithelium (RPE) are the primary location of mutations underlying many forms of inherited retinal degeneration for which there is currently no treatment. Therefore, a major goal in the field of vision research is to develop improved technology for gene delivery to these cells. This proposal aims to address this problem by creating novel adeno-associated (AAV) vectors capable of targeting PRs and RPE when delivered into the canine vitreous. We have selected the dog as it is a relevant large animal model that shares similar globe volume and retinal structure with humans, as well as naturally- occurring mutations that result in phenotypically similar retinal diseases as those identified in patients. Naturally occurring serotypes of AAVs are unable to penetrate structural barriers of the retina, and therefore therapeutic delivery of DNA to PRs and RPE has required until now that the viral vector be injected into the subretinal space. Subretinal injections entail the passage of a needle through the retina as well as a transient retinal detachment that separates the RPE from the PRs. This microsurgical technique requires general anesthesia, delivers the viral vector to a limited area of the retina/RPE, and has been associated in preclinical safety studies and human clinical trials with retinal thinning under the fovea and the formation of macular holes. Recently, AAV vectors have been optimized for increased targeting of PRs and RPE following intravitreal delivery, which would provide easier, safer and more extensive targeting of the PRs and RPE than vectors delivered via the subretinal route. Successful results have been achieved in mice, however, when tested in large animals these vectors were inefficient due to differences in retinal structure. Based on strong initial results in mice, we will use a similar directed evolution approach to select, from a mixture of highly diverse libraries of mutated AAVs, individual variants with the novel ability to traverse structural barriers and infect the dog outer retina from the vitreous. Resulting vectors will be characterized by packaging GFP and analyzing expression profiles. We will then test whether the genetic features that increase transduction in dogs are also sufficient to improve infection of the non-human primate outer retina. Furthermore, we will use deep sequencing to analyze rounds of selection, in order to elucidate at which steps diversity is reduced and to determine if the final outcome of directed evolution can be predicted from the initial rounds. The identified novel variants will be used to test corrective gene therapies in the rcd1 dog, a model of PR disease caused by a mutation in the rod-specific PDE6¿ gene, as well as in the RPE65 mutant dog, a model of Leber's congenital amaurosis due to a genetic defect in the RPE. We will then measure whether intravitreal injections provide equivalent or better rescue compared to subretinal injections by evaluating retinal structure and function. Together, these experiments will provide a diverse training experience and valuable preclinical data for novel gene therapy treatments in the retina.
|
0.915 |